Aptar Pharma, a provider of drug delivery systems, has acquired all device technology assets from SipNose Nasal Delivery Systems’ portfolio, expanding its presence in the intranasal drug delivery market.

This strategic move will enhance Aptar Pharma's patent product portfolio and support the development of new products.

SipNose's diverse range of devices are designed to target specific areas within the nasal cavity.

These devices enable precise delivery of local, systemic and direct-to-brain applications, which is crucial for a variety of therapies.

Aptar Pharma Prescription president Alex Theodorakis said: “Our nasal systems’ proven capabilities have brought added value to our customers and further convenience for patients worldwide for over 30 years.

“As the nasal market looks to develop new drugs to address unmet patient needs, this transaction will enhance Aptar’s portfolio of nasal drug delivery systems with a focus on CNS [central nervous system] diseases.”

The acquisition of SipNose's delivery systems including liquid and dry powder intranasal technologies is expected to enhance Aptar Pharma's expertise in the nose-to-brain pathway.

This will facilitate further development and scientific research within the sector.

Aptar Pharma business development director Reenal Gandhi said: “SipNose is focused on development and innovation in intranasal drug delivery. Integrating these assets into our portfolio underlines Aptar Pharma’s continued expansion into the nasal drug delivery space.”

Founded in 2011, SipNose is focused on the development of nasal drug delivery solutions by combining technological and engineering expertise with medical and scientific knowledge.

Last month, Aptar Digital Health joined forces with Guy’s and St Thomas’ NHS Foundation Trust in the UK to assess the impact of its digital Respiratory Disease Management Platform on asthma patients in a trial.